Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. root
  2. SOMAVERT
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
  • Date 05 March 2014
  • Documents : 3
  • History
Download opinion
Listen Listen
Add to my selection
  • Clinical Benefit
Quote this publication
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

SOMAVERT

-
Opinions on drugs - Posted on Jun 06 2014

Reason for request

Renewal of inclusion.

-


Clinical Benefit

Moderate

Moderate


Documents

  • SOMAVERT_05032014_AVIS_CT13381 Xvox
  • SOMAVERT_05032014_SYNTHESE_CT13381 Xvox

English version

  • SOMAVERT_CT13381_English version Xvox
All our publications
    Congenital, genetic and rare diseases Drug therapy Endocrine system diseases

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
aJm3Z0gMv4t9NQxw